DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01509755

CompletedPhase 2

Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes

Dose-response Relationship of Five Dose Levels of NNC90-1170 and Placebo on Glycaemic Control in Type 2 Diabetic Patients Compared to OHA Treatment. A 12-week Multi-centre, Double-blind, Randomised, Parallel Group Trial With an Open Labelled OHA Arm

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

29

Recruiting sites

—

Enrollment

196

estimated

Study population

Type 2 diabetes

Key I/E criterion

•HbA1c 7.5-10%

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01509755
Org study IDNN2211-1310

Timeline

Milestones

Study first posted2012-01-13estimated
Last update posted2017-01-24estimated
Study start2000-10 (month precision)
Primary completion2001-10actual (month precision)
Study completion2001-10actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age30 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Subjects with type 2 diabetes
•Duration of diabetes at least 3 months
•Both diet treated and patients in therapy with OHA (oral hypoglycemic agents)
•Body Mass Index maximum 40 kg/m^2
•HbA1c based on analysis from central laboratory: Between 7.5-10.0%, both inclusive, for diet treated, or maximum 9.0% for OHA treated

Exclusion criteria

•Liver or renal disease
•Cardiac problems
•Uncontrolled treated/untreated hypertension
•Proliferative retinopathy
•Recurrent severe hypoglycaemia as judged by the Investigator
•Known or suspected allergy to trial product or related products
•Use of any drug (except for OHAs) which in the Investigator's opinion could interfere with the blood glucose level

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
4
Safety / tolerability / PK
1

Glycemic / diabetes

4 endpoints
Primary/protocol endpoint

HbA1c (glycosylated haemoglobin)

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Fasting plasma glucose

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint/low confidence

Fructosamine

change from baseline, improvement

Secondary/protocol endpoint

7-point blood glucose profile

descriptive, improvement

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Adverse events

Treatment-emergent AEs (any)

descriptive, event

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.